Your search returned 24 results. Subscribe to this search

|
1. Alirocumab Added to High-Intensity Statin Therapy and Coronary Atherosclerosis in Patients With Acute Myocardial Infarction

by Garcia-Garcia, Hector M MHVI.

Published: 2022; ; ; Citation: JAMA. 328(9):891, 2022 09 06..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Calderon AT; Garcia-Garcia HM; Sanz-Sanchez J.UI/PMID: 36066524.Digital Object Identifier: https://dx.doi.org/10.1001/jama.2022.11830 (Click here)
2. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study

by Swain, Sandra M.

Published: 2022; ; ; ; Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10.; .Department: Associate Dean for Research Development.Publication: Journal Article.Article type: Journal Article.Full author list: Barrios C; Bonnefoi H; Boulet T; De Laurentiis M; Ellis PA; Fehrenbacher L; Gianni L; Gralow J; Harbeck N; Huang CS; Im SA; Im YH; Ito Y; Krop IE; Liu H; Macharia H; Nowecki Z; Shah J; Song C; Swain SM; Toi M; Trask P; Winer EP.UI/PMID: 34890214.Digital Object Identifier: https://dx.doi.org/10.1200/JCO.21.00896 (Click here)
3. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50

by Rao, Suman.

Published: 2021; ; ; Citation: Journal of Clinical Oncology. 39(21):2339-2349, 2021 07 20.; .Institution: MedStar Franklin Square Medical Center.Publication: Journal Article.Article type: Journal Article.Full author list: Brahmer JR; Csoszi T; Cuffe S; Fulop A; Gottfried M; Hotta K; Hui R; Jensen E; Leal TA; O'Brien M; Peled N; Pietanza MC; Rao S; Reck M; Riess JW; Robinson AG; Rodriguez-Abreu D; Tafreshi A; Zhao B.UI/PMID: 33872070.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1200/JCO.21.00174 (Click here)
4. Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study

by Desai, Sanjal.

Published: 2021; ; ; Citation: Leukemia & Lymphoma. 62(8):1816-1827, 2021 08.; .Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Ahn IE; Desai S; Drinkwater DC; Farooqui MZ; Gaglione EM; Herman SEM; Hughes TE; Lindorfer MA; Lotter J; Maric I; Marti GE; Mo C; Nichols C; Nierman P; Pleyer C; Soto S; Stetler-Stevenson M; Sun C; Superata J; Taylor RP; Tian X; Valdez J; Wake L; Wiestner A; Yuan CM.UI/PMID: 33653216.Digital Object Identifier: https://dx.doi.org/10.1080/10428194.2021.1888379 (Click here)
5. A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor

by Alzeer, Ali Hazem; Zaemes, Jacob.

Published: 2020; ; Citation: Immunotherapy. 12(12):861-867, 2020 08.; .Institution: MedStar Washington Hospital Center.Department: Internal Medicine Residency; Pathology Residency.Publication: Journal Article.Article type: Journal Article.Full author list: Alzeer A; Atkins M; Villa K; Zaemes J.UI/PMID: 32640856.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.2217/imt-2020-0139 (Click here)
6. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

by Priebat, Dennis A.

Published: 2020; ; ; Citation: Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.; .Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Attia S; Bolejack V; Burgess M; Davis LE; Hu J; Keung EZ; Lazar AJ; Movva S; Okuno S; Parra Cuentas E; Priebat DA; Reed DR; Reinke DK; Reuben A; Riedel RF; Rodrigues-Canales J; Roland CL; Salazar R; Schuetze SM; Tawbi HA; Van Tine BA; Wang WL; Wargo JA.UI/PMID: 31900276.Digital Object Identifier: https://dx.doi.org/10.1158/1078-0432.CCR-19-1824 (Click here)
7. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study

by Alsaadi, Dana; Charabaty, Aline; Jennings, Joseph.

Published: 2018; Citation: Journal for Immunotherapy of Cancer. 6(1):142, 2018 Dec 05..Institution: MedStar Washington Hospital Center.Department: Gastroenterology/Hepatology.Publication: Journal Article.Article type: Journal Article.Full author list: Abu-Sbeih H; Ali FS; Alsaadi D; Charabaty A; Gong Z; Jennings J; Luo W; Richards DM; Wang Y.UI/PMID: 30518410.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1186/s40425-018-0461-4 (Click here)
8. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab

by Vakiti, Anusha; Pilla, Ravi; Alhaj-Moustafa, Muhamad; Fitzpatrick, Kelly.

Published: ; 2019Citation: Journal of Oncology Pharmacy Practice. 25(4):1011-1015, 2019 Jun..Institution: MedStar Washington Hospital Center; Washington Cancer Institute.Department: Medicine/General Internal Medicine.Publication: Journal Article.Article type: Journal Article.Full author list: Vakiti A; Singh D; Pilla R; Alhaj-Moustafa M; Fitzpatrick KW.UI/PMID: 29768958.Digital Object Identifier: https://dx.doi.org/10.1177/1078155218774895 (Click here)
9. Advances in Stroke 2017. [Review]

by Zorowitz, Richard D.

Published: 2018Citation: Stroke. 49(5):e174-e199, 2018 05..Institution: MedStar National Rehabilitation Network.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Bernhardt J; Zorowitz RD; Becker KJ; Keller E; Saposnik G; Strbian D; Dichgans M; Woo D; Reeves M; Thrift A; Kidwell CS; Olivot JM; Goyal M; Pierot L; Bennett DA; Howard G; Ford GA; Goldstein LB; Planas AM; Yenari MA; Greenberg SM; Pantoni L; Amin-Hanjani S; Tymianski M.UI/PMID: 29669874.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1161/STROKEAHA.118.021380 (Click here)
10. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

by Priebat, Dennis A.

Published: 2017Citation: Lancet Oncology. 18(11):1493-1501, 2017 Nov.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S.UI/PMID: 28988646.Digital Object Identifier: https://dx.doi.org/10.1016/S1470-2045(17)30624-1 (Click here)
11. Pertuzumab for the treatment of breast cancer: a safety review. [Review]

by Swain, Sandra M.

Published: 2016Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Gao J; Swain SM.UI/PMID: 26982349.Digital Object Identifier: https://dx.doi.org/10.1517/14740338.2016.1167185 (Click here)
12. Reply to a. Avan et Al

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 33(15):1712, 2015 May 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Baselga J; Clark E; Kiermaier A; Swain S.UI/PMID: 25870094.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2015.60.8398 (Click here)
13. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Baselga J; Cortes J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM.UI/PMID: 25332247.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2013.54.5384 (Click here)
14. Pertuzumab for the treatment of breast cancer. [Review]

by Swain, Sandra M; Lynce, Filipa.

Citation: Cancer Investigation. 32(8):430-8, 2014 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: Lynce F; Swain SM.UI/PMID: 24921704.Digital Object Identifier: http://dx.doi.org/10.3109/07357907.2014.922570 (Click here)
15. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus

by Weinstein, Arthur.

Citation: Journal of Rheumatology. 41(2):300-9, 2014 Feb..Institution: MedStar Washington Hospital Center.Department: Medicine/Rheumatology.Publication: Journal Article.Article type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial.Full author list: Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA; LBSL02/99 Study Group.UI/PMID: 24187095.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.3899/jrheum.121368 (Click here)
16. Pertuzumab: increasing the options

by Nunes, Raquel; Swain, Sandra M.

Citation: Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Nunes R; Swain SM.UI/PMID: 24855727.Online Access: Click here to access online
17. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

by Swain, Sandra M.

Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM.UI/PMID: 23868905.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdt274 (Click here)
18. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

by Swain, Sandra M.

Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J.UI/PMID: 23969513.Digital Object Identifier: http://dx.doi.org/10.1097/CAD.0000000000000016 (Click here)
19. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

by Swain, Sandra M.

Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 24262440.Digital Object Identifier: http://dx.doi.org/10.1093/jnci/djt321 (Click here)
20. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies

by Swain, Sandra M.

Citation: Clinical Cancer Research. 19(13):3681-92, 2013 Jul 1..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C.UI/PMID: 23685835.Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.CCR-12-3635 (Click here)
21. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

by Henshaw, Robert M.

Citation: Lancet Oncology. 14(9):901-8, 2013 Aug..Institution: MedStar Washington Hospital Center.Department: Orthopedic Oncology.Publication: Journal Article.Article type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't.Full author list: Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I.UI/PMID: 23867211.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(13)70277-8 (Click here)
22. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

by Swain, Sandra M.

Citation: Oncologist. 18(3):257-64, 2013..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Ewer MS; Cortes J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J.UI/PMID: 23475636.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2012-0448 (Click here)
23. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review]

by Swain, Sandra M.

Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: O'Sullivan CC; Swain SM.UI/PMID: 23530718.Digital Object Identifier: http://dx.doi.org/10.1517/14712598.2013.783007 (Click here)
24. Avastin withdrawal symptoms

by Lynce, Filipa; Swain, Sandra M.

Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Editorial; Research Support, Non-U.S. Gov't.Full author list: Lynce F; Swain SM.UI/PMID: 22263961.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1517/14656566.2012.652088 (Click here)

Powered by Koha